drugset / Trial / NCT05998759
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
Phase 2
Recruiting
296 enrolled
Beijing Hospital
Changhai Hospital · collabFirst Affiliated Hospital, Sun Yat-Sen University · collabFirst Hospital of China Medical University · collabGuangdong Provincial People's Hospital · collabInstitute of Hematology & Blood Diseases Hospital, China · collabPeking University People's Hospital · collabPeking University Third Hospital · collabPeople's Hospital of Xinjiang Uygur Autonomous Region · collabRenJi Hospital · collabSecond Xiangya Hospital of Central South University · collabShandong Provincial Hospital · collabShanxi Bethune Hospital · collabThe Affiliated Hospital of Inner Mongolia Medical University · collabThe First Affiliated Hospital of Anhui Medical University · collabThe First Affiliated Hospital of China University of Science and Technology (Anhui Provincial) · collabThe First Affiliated Hospital of Zhengzhou University · collabThe First People's Hospital of Yunnan · collabTianjin First Central Hospital · collabTianjin Medical University General Hospital · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collabWest China Hospital · collabXiangya Hospital of Central South University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia.
Timeline
- Start
- 2023-12-02
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |